Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution

doi:10.4251/wjgo.v17.i1.96822

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (419)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

HTML

194

Figures (1-1)

Tables (1-5)

Sum=315

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=89

Jan 15, 2025 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822

Table 5 DPYD polymorphisms analysis in Italian cancer patients

Feature	TOSCA trial[20]	TRIBE trial[21]	IRCCS Pascale[22]
Setting	Colon cancer high-risk stage 2 or stage 3	Colo-rectal cancer stage 4	Gastrointestinal malignancies
Treatment	FOLFOX/CAPOX	FOLFOXIRI/FOLFIRI + bevacizumab	Patients candidates for fluoropyrimidines
Patients	508	439	1000
Total number of tested variants	10	3	5
Prevalence of the four recommended variants in heterozygosity	19/508 (3.7)	10/439 (2.3)¹	39/1000 (3.9)
Prevalence of the four recommended variants + DPYD6 in heterozygosity	84/508 (16.5)	0/439 (0)²	180/1000 (18)
Prevalence of the four recommended variants + DPYD6 in homozygosity	5/508 (1.0)³	0/439 (0)²	5/1000 (0.5)³

¹HapB3 not analyzed.

²HapB3 and DPYD6 not analyzed.

³All DPYD6.

Data are n (%). TOSCA: A randomized trial investigating the role of oxaliplatin, fluorouracil and leucovorin calcium-4 regimen duration (3 months vs 6 months) and bevacizumab as adjuvant therapy for patients with stage 2/3 colon cancer; TRIBE: Phase 3 randomized trial of oxaliplatin, irinotecan, fluorouracil, and leucovorin calcium + bevacizumab vs irinotecan, fluorouracil, and leucovorin calcium + bevacizumab as first-line treatment for metastatic colorectal cancer. CAPOX: Capecitabine and oxaliplatin; FOLFIRI: Irinotecan, fluorouracil, and leucovorin calcium; FOLFOX: Oxaliplatin, fluorouracil, and leucovorin calcium; FOLFOXIRI: Oxaliplatin, irinotecan, fluorouracil, and leucovorin calcium; IRCCS: Scientific institute for research, hospitalization and healthcare.

Citation: D'Amato M, Iengo G, Massa N, Carlomagno C. Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution. World J Gastrointest Oncol 2025; 17(1): 96822
URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96822.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96822